tetano
Editor, Senior Moderator
Clin Infect Dis
. 2020 Jun 25;ciaa848.
doi: 10.1093/cid/ciaa848. Online ahead of print.
Sensitivity of Nasopharyngeal Swabs and Saliva for the Detection of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)
Alainna J Jamal[SUP] 1 2 3 [/SUP], Mohammad Mozafarihashjin[SUP] 2 [/SUP], Eric Coomes[SUP] 3 [/SUP], Jeff Powis[SUP] 4 [/SUP], Angel X Li[SUP] 2 [/SUP], Aimee Paterson[SUP] 2 [/SUP], Sofia Anceva-Sami[SUP] 2 [/SUP], Shiva Barati[SUP] 2 [/SUP], Gloria Crowl[SUP] 2 [/SUP], Amna Faheem[SUP] 2 [/SUP], Lubna Farooqi[SUP] 2 [/SUP], Saman Khan[SUP] 2 [/SUP], Karren Prost[SUP] 5 [/SUP], Susan Poutanen[SUP] 2 3 [/SUP], Maureen Taylor[SUP] 4 [/SUP], Lily Yip[SUP] 5 [/SUP], Xi Zoe Zhong[SUP] 2 [/SUP], Allison J McGeer[SUP] 1 2 3 [/SUP], Samira Mubareka[SUP] 3 5 [/SUP], Toronto Invasive Bacterial Diseases Network COVID-19 Investigators
Affiliations
Abstract
We enrolled 91 consecutive in-patients with COVID-19 at six hospitals in Toronto, Canada, and tested one nasopharyngeal swab/saliva sample pair from each patient using real-time reverse transcriptase polymerase chain reaction for SARS-CoV-2. Sensitivity was 89% for nasopharyngeal swabs and 72% for saliva (p=0.02); difference in sensitivity was greatest for sample pairs collected later in illness.
Keywords: COVID-19; SARS-CoV-2; nasopharyngeal swab; saliva.
. 2020 Jun 25;ciaa848.
doi: 10.1093/cid/ciaa848. Online ahead of print.
Sensitivity of Nasopharyngeal Swabs and Saliva for the Detection of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)
Alainna J Jamal[SUP] 1 2 3 [/SUP], Mohammad Mozafarihashjin[SUP] 2 [/SUP], Eric Coomes[SUP] 3 [/SUP], Jeff Powis[SUP] 4 [/SUP], Angel X Li[SUP] 2 [/SUP], Aimee Paterson[SUP] 2 [/SUP], Sofia Anceva-Sami[SUP] 2 [/SUP], Shiva Barati[SUP] 2 [/SUP], Gloria Crowl[SUP] 2 [/SUP], Amna Faheem[SUP] 2 [/SUP], Lubna Farooqi[SUP] 2 [/SUP], Saman Khan[SUP] 2 [/SUP], Karren Prost[SUP] 5 [/SUP], Susan Poutanen[SUP] 2 3 [/SUP], Maureen Taylor[SUP] 4 [/SUP], Lily Yip[SUP] 5 [/SUP], Xi Zoe Zhong[SUP] 2 [/SUP], Allison J McGeer[SUP] 1 2 3 [/SUP], Samira Mubareka[SUP] 3 5 [/SUP], Toronto Invasive Bacterial Diseases Network COVID-19 Investigators
Affiliations
- PMID: 32584972
- DOI: 10.1093/cid/ciaa848
Abstract
We enrolled 91 consecutive in-patients with COVID-19 at six hospitals in Toronto, Canada, and tested one nasopharyngeal swab/saliva sample pair from each patient using real-time reverse transcriptase polymerase chain reaction for SARS-CoV-2. Sensitivity was 89% for nasopharyngeal swabs and 72% for saliva (p=0.02); difference in sensitivity was greatest for sample pairs collected later in illness.
Keywords: COVID-19; SARS-CoV-2; nasopharyngeal swab; saliva.